Wang, C.; Hu, D.; Zhou, D.; Hu, X.; Liu, R.; Ma, H.; Wang, W.; Tao, M.; Wang, Z.; Zhou, M.; et al. Knock Down of HMGA2 Suppresses Colorectal Cancer Progression through Inhibiting Angiogenesis via Compromising VEGFR2 Signaling in HUVECs. Indian Journal of Pharmaceutical Sciences 2023, 81, doi:10.36468/pharmaceutical-sciences.spl.620.
Wang, C.; Hu, D.; Zhou, D.; Hu, X.; Liu, R.; Ma, H.; Wang, W.; Tao, M.; Wang, Z.; Zhou, M.; et al. Knock Down of HMGA2 Suppresses Colorectal Cancer Progression through Inhibiting Angiogenesis via Compromising VEGFR2 Signaling in HUVECs. Indian Journal of Pharmaceutical Sciences 2023, 81, doi:10.36468/pharmaceutical-sciences.spl.620.
Wang, C.; Hu, D.; Zhou, D.; Hu, X.; Liu, R.; Ma, H.; Wang, W.; Tao, M.; Wang, Z.; Zhou, M.; et al. Knock Down of HMGA2 Suppresses Colorectal Cancer Progression through Inhibiting Angiogenesis via Compromising VEGFR2 Signaling in HUVECs. Indian Journal of Pharmaceutical Sciences 2023, 81, doi:10.36468/pharmaceutical-sciences.spl.620.
Wang, C.; Hu, D.; Zhou, D.; Hu, X.; Liu, R.; Ma, H.; Wang, W.; Tao, M.; Wang, Z.; Zhou, M.; et al. Knock Down of HMGA2 Suppresses Colorectal Cancer Progression through Inhibiting Angiogenesis via Compromising VEGFR2 Signaling in HUVECs. Indian Journal of Pharmaceutical Sciences 2023, 81, doi:10.36468/pharmaceutical-sciences.spl.620.
Abstract
Background: HMGA2 encodes a small non histone chromatin-associated protein that has no intrinsic transcriptional activity, but can modulate transcription by altering the chromatin architecture. HMGA2 was found overexpressed in a variety of epithelial and mesenchymal tumors and promoted invasion and metastasis in most malignant epithelial tumors. A recent study showed that P53 inhibited CRC progression by targeting HMGA2. However, the mechanism by which HMGA2 affect angiogenesis in CRC has not been clarified. Methods: The expression of HMGA2 was analyzed by IHC, WB and bio infomatic analysis. Cbioportal and mexpress online tools were applied to explore the CNV and methylation of HMGA2 in CRC patients. Single cell data from GEO was used to examine the specific cell type that contribute to the high HMGA2 expression in CRC. Lentivirus was used to knock down HMGA2 in CRC cells and HUVECs was used to study angiogenesis. Results: In the current study, we first detected the expression pattern of HMGA2 in CRC patients and evaluated its clinical values and CNV amplification could possibly contribute to the up regulation of HMGA2 in CRC patients. By analyzing CRC single cell data we found that HMGA2 was specifically up regulated in the colorectal epithelial cells. Furthermore, knocking down of HMGA2 suppresses angiogenesis via dual regulation of VEGF-A and SEMA3A in CRC through inactivating VEGRR2 pathway in HUVECs. Conclusions: HMGA2 might be a promising prognostic marker and target for treating advanced CRC patients.
Keywords
HMGA2; Colorectal cancer; Sema3A; VEGFA
Subject
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
